Alkermes Plc (ALKS)

45.12
NASDAQ : Health Technology
Prev Close 45.12
Day Low/High 0.00 / 0.00
52 Wk Low/High 39.54 / 71.22
Avg Volume 856.30K
Exchange NASDAQ
Shares Outstanding 155.04M
Market Cap 6.91B
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Alkermes Receives $50 Million Payment From Biogen Following Review Of Preliminary Gastrointestinal Tolerability Data From The Ongoing BIIB098 Clinical Development Program

Alkermes Receives $50 Million Payment From Biogen Following Review Of Preliminary Gastrointestinal Tolerability Data From The Ongoing BIIB098 Clinical Development Program

-- Novel, Oral Fumarate Therapy Intended to Provide a Differentiated Gastrointestinal Tolerability Profile --

American Airlines Is Caught in a Downward Current, Plus 4 Other Stocks That Look Good Short

AAL, UBS, CYOU, LOGM and ALKS were all recently downgraded by TheStreet's Quant Ratings service.

Alkermes To Host Webcast And Conference Call To Discuss ALKS 3831 Development Program

-- Company to Present New Metabolic Data and Provide Overview of Clinical Development Program at 8:30 a.m. ET on Thursday, May 10 --

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ENVA, ERIC, GM, MHH, PJC, SONA, SVVC Downgrades: ALKS, APOG, IDT, MJCO, TYPE Initiations: CKPT Read on to get TheStreet Quant Ratings' detailed report:

Alkermes Completes Patient Enrollment In Pivotal Weight Study Of ALKS 3831 For Schizophrenia

-- Topline Results From ENLIGHTEN-2 Study Expected in Q4 2018 --

Spotify, Alkermes, Sorrento Therapeutics: 'Mad Money' Lightning Round

Spotify, Alkermes, Sorrento Therapeutics: 'Mad Money' Lightning Round

Jim Cramer highlights Spotify, Alkermes, Sorrento Therapeutics, Thermo Fisher Scientific, Kohlberg Kravis Roberts, and more.

Unreasonable Earnings Expectations?: Cramer's 'Mad Money' Recap (Monday 4/16/18)

Unreasonable Earnings Expectations?: Cramer's 'Mad Money' Recap (Monday 4/16/18)

Washington receded and earnings came to the fore, but we're still seeing insane values and some surprises, says Jim Cramer.

Alkermes Wins Quick Reversal From FDA on Antidepressant Drug

Alkermes Wins Quick Reversal From FDA on Antidepressant Drug

Two weeks ago, the agency told Alkermes it needed more trials for antidepressant drug candidate ALKS-5461. The agency, however, had a change of heart, sending shares jumping on the news.

American Medical Association Rejects Idea of Time Limits on Opioid Scripts

American Medical Association Rejects Idea of Time Limits on Opioid Scripts

While more than half the states in the U.S. have passed time limits on opioid prescription as a way to battle the epidemic, the AMA says that should be left up to the doctor and patient.

Two to Buy on the Dip

Two to Buy on the Dip

Talk of intensifying trade war is creating some bargains for investors.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Alkermes Plc

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Alkermes Plc

Levi & Korsinsky announces it has commenced an investigation of Alkermes plc ("Alkermes" or "the Company") (NASDAQGS:ALKS) concerning possible violations of federal securities laws.

Dow Comes Off Session Lows, Finishes Day Down More Than 400 Points

Dow Comes Off Session Lows, Finishes Day Down More Than 400 Points

Stocks finish down sharply on Monday, the first trading day of the second quarter, after China's Ministry of Finance announces new tariffs of up to 25% on certain U.S. products.

Alkermes Surprised, Angered by FDA Rejection of Antidepressant

Alkermes Surprised, Angered by FDA Rejection of Antidepressant

Alkermes says the rejection of antidepressant drug ALKS 5461 is a head-scratcher, and it's calling for a prompt meeting with the regulator to get to the bottom of the decision.

Trump's Opioid Plan Gives Alkerme's Vivitrol Drug a Sales Boost

Trump's Opioid Plan Gives Alkerme's Vivitrol Drug a Sales Boost

Alkermes has spent money lobbying and donating to elected officials, and in the White House opioid plan, it seems to have paid off, as opioid blocker Vivitrol becomes part of prison protocol.

ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alkermes Plc To Contact The Firm

ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alkermes Plc To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alkermes plc ("Alkermes" or the "Company") (NASDAQ:ALKS) of the January 22, 2018 deadline to seek the role of lead plaintiff in a...

Scott+Scott, Attorneys At Law, LLP Reminds Investors Of January 22 Deadline In Securities Class Action Against Alkermes Plc (ALKS)

Scott+Scott, Attorneys At Law, LLP Reminds Investors Of January 22 Deadline In Securities Class Action Against Alkermes Plc (ALKS)

Scott+Scott, Attorneys at Law, LLP ("Scott+Scott"), a national securities and consumer rights litigation firm, reminds investors that a class action lawsuit is pending against Alkermes plc (NASDAQ: ALKS) ("Alkermes" or...

ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alkermes Plc To Contact The Firm

ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alkermes Plc To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alkermes plc ("Alkermes" or the "Company") (NASDAQ:ALKS) of the January 22, 2018 deadline to seek the role of lead plaintiff in a...

Alkermes Is Getting Ready for a Rally

Alkermes Is Getting Ready for a Rally

ALKS's choppy trading period may be coming to a close.

Alkermes: Cramer's Top Takeaways

Alkermes: Cramer's Top Takeaways

Richard Pops, chairman and CEO of Alkermes, tells Jim Cramer about the company's 2018 outlook for drug development.

Good News Matters in This Market: Cramer's 'Mad Money' Recap (Monday 1/8/18)

Good News Matters in This Market: Cramer's 'Mad Money' Recap (Monday 1/8/18)

From global growth and bonds to index funds, Jim Cramer explains why stocks keep going up, giving the Dow and Nasdaq their best start to the new year since 2006.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Alkermes Plc Of Class Action Lawsuit And Upcoming Deadline - ALKS

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Alkermes Plc Of Class Action Lawsuit And Upcoming Deadline - ALKS

Pomerantz LLP announces that a class action lawsuit has been filed against Alkermes plc ("Alkermes" or the "Company") (NASDAQ:ALKS) and certain of its officers.

TheStreet Quant Rating: D (Sell)